**Altasciences’ Patient Access**

- **500+** patients with Hepatitis B Virus (HBV) Infection
- **5,500+** patients with Hepatitis C Virus (HCV) Infection, genotypes 1, 2 and others
- Access to both treatment-naïve and virologically suppressed patients
- Access to genotyping services with fast reporting timelines
- Ongoing outreach efforts to maintain and increase participant database
- Searchable database to qualify Inclusion/exclusion criteria for pre-existing conditions, demographics, medication use, and body mass index (BMI)
- Dedicated clinical facility to accommodate long-term stays

**Recent Experience**

- **A Study Evaluating NCE in Virologically Suppressed Subjects with Chronic Hepatitis B Virus Infection**
- **A Study Evaluating NCE in Treatment-Naïve Subjects with Chronic Hepatitis B**
- **Study Assessing Single and Multiple Doses of NCE in Healthy and Hepatitis C Virus (HCV)-Infected Participants**
- **A Phase Ib Study Assessing NCE efficacy in Treatment-Naïve Adults With Chronic Hepatitis B**

**Clinical Expertise**

- Adaptive designs involving healthy participants and patient arms
- Setup for medical, scientific, regulatory and operational procedures
- Support services, including customized protocol design, data management, bioanalysis, biostatistics and reporting
- Administration of medication via multiple routes, including parenterals

contact@altasciences.com
altasciences.com
Support Services

**Bioanalysis**
- Bioanalytical capabilities are supported by over 100 highly-trained specialists, working with the latest equipment in state-of-the-art, purpose-built laboratories
- High throughput bioassays for drug quantitation (operating 24/7), capacity of 60,000 samples per month
- Method feasibility, transfer, development and validations in multiple matrices
- LC-MS/MS and ligand binding assay capabilities

**Toxicokinetics and Pharmacokinetic Analysis**
- Comprehensive preclinical TK and clinical PK and PD data analysis and interpretation
- Robust non-compartmental analysis using WinNonlin® v8 (Phoenix)
- Rapid turnaround for interim PK evaluation between dose escalation cohorts
- Stand-alone report and/or CSR integration

**Data Management**
- Team with over 20 years of experience
- Electronic Data Capture
- CDISC standards fully integrated in workflow
- Medical coding using latest versions of medical dictionaries (MedDRA, WHO-DDE)
- Database lock available typically within 2 to 4 weeks of last subject’s final visit

**Medical Writing**
- Team with over 20 years of experience
- Study design in line with current regulations
- Clinical trial protocol development, review and evaluation
- Integrated ICH E3-compliant clinical study report (CSR)

**Project Management**
- Project Manager (Project Leader) oversees the complete program conduct and deliverables
- Extensive expertise in managing single or multiple site clinical trials, across a wide range of therapeutic areas
- Close collaboration with key internal and external stakeholders ensures seamless and timely communication for successful project completion

**Biostatistics**
- All Programming done using SAS®
- Randomization list
- Statistical Analysis Plan, including mock TFLs
- Statistical results and appendices (TFLs) for CSR
- Reconciliation of external data e.g. safety lab
- Creation of CDISC-compliant FDA submission-ready package

contact@altasciences.com
altasciences.com